Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PolyHeme in traumatic hemorrhagic shock
NCT00076648Phase 3Unknown
- Sponsor
- Northfield Laboratories
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in hemorrhagic shock comparing PolyHeme with Standard of Care (2 arms). Primary endpoint: 30-day all-cause mortality. Status: unknown.
02
Drugs
poly sfh-p
03
Conditions
hemorrhagic shock
Beyond the preview
Go deeper on NCT00076648.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00076648.